Kirsten Koehorst-ter Huurne1, Kris Movig2, Paul van der Valk1, Job van der Palen1,3, Marjolein Brusse-Keizer1. 1. a Department of Pulmonary Medicine , Medisch Spectrum Twente , Enschede , the Netherlands. 2. b Department of Clinical Pharmacy , Medisch Spectrum Twente , Enschede , the Netherlands. 3. c Department of Research Methodology , Measurement, and Data Analysis, University of Twente , Enschede , Netherlands.
Abstract
OBJECTIVE: To study differences in adherence to common inhaled medications in COPD. METHODS: Adherence of 795 patients was recorded from pharmacy records over 3 years in the COMIC cohort. It was expressed as percentage and deemed good at ≥75-≤125%, sub-optimal ≥50-<75%, and poor <50% (underuse) or >125% (overuse). Most patients used more than one medication, so we present 1379 medication periods. RESULTS: The percentages of patients with good therapy adherence ranged from 43.2 (beclomethasone) -75.8% (tiotropium); suboptimal from 2.3 (budesonide) -23.3% (fluticasone); underuse from 4.4 (formoterol/budesonide) -18.2% (beclomethasone); and overuse from 5.1 (salmeterol) -38.6% (budesonide). Patients using fluticasone or salmeterol/fluticasone have a 2.3 and 2.0-fold increased risk of suboptimal versus good adherence compared to tiotropium. Patients using salmeterol/fluticasone or beclomethasone have a 2.3- and 4.6-fold increased risk of underuse versus good adherence compared to tiotropium. Patients using budesonide, salmeterol/fluticasone, formoterol/budesonide, ciclesonide and beclomethasone have an increased risk of overuse versus good adherence compared to tiotropium. Adherence to inhalation medication is inversely related to lung function. CONCLUSION: Therapy adherence to inhalation medication for the treatment of COPD is in our study related to the medication prescribed. Tiotropium showed the highest percentage of patients with good adherence, followed by ciclesonide, both dosed once daily. The idea of improving adherence by using combined preparations cannot be confirmed in this study. Further research is needed to investigate the possibilities of improving adherence by changing inhalation medication.
OBJECTIVE: To study differences in adherence to common inhaled medications in COPD. METHODS: Adherence of 795 patients was recorded from pharmacy records over 3 years in the COMIC cohort. It was expressed as percentage and deemed good at ≥75-≤125%, sub-optimal ≥50-<75%, and poor <50% (underuse) or >125% (overuse). Most patients used more than one medication, so we present 1379 medication periods. RESULTS: The percentages of patients with good therapy adherence ranged from 43.2 (beclomethasone) -75.8% (tiotropium); suboptimal from 2.3 (budesonide) -23.3% (fluticasone); underuse from 4.4 (formoterol/budesonide) -18.2% (beclomethasone); and overuse from 5.1 (salmeterol) -38.6% (budesonide). Patients using fluticasone or salmeterol/fluticasone have a 2.3 and 2.0-fold increased risk of suboptimal versus good adherence compared to tiotropium. Patients using salmeterol/fluticasone or beclomethasone have a 2.3- and 4.6-fold increased risk of underuse versus good adherence compared to tiotropium. Patients using budesonide, salmeterol/fluticasone, formoterol/budesonide, ciclesonide and beclomethasone have an increased risk of overuse versus good adherence compared to tiotropium. Adherence to inhalation medication is inversely related to lung function. CONCLUSION: Therapy adherence to inhalation medication for the treatment of COPD is in our study related to the medication prescribed. Tiotropium showed the highest percentage of patients with good adherence, followed by ciclesonide, both dosed once daily. The idea of improving adherence by using combined preparations cannot be confirmed in this study. Further research is needed to investigate the possibilities of improving adherence by changing inhalation medication.
Entities:
Keywords:
COPD; adherence; inhalation medication; lung function
Authors: Kirsten Koehorst-Ter Huurne; Sharina Kort; Job van der Palen; Wendy Jc van Beurden; Kris Ll Movig; Paul van der Valk; Marjolein Brusse-Keizer Journal: Int J Chron Obstruct Pulmon Dis Date: 2016-07-26
Authors: Emanuel Citgez; Job van der Palen; Kirsten Koehorst-Ter Huurne; Kris Movig; Paul van der Valk; Marjolein Brusse-Keizer Journal: BMJ Open Respir Res Date: 2016-06-17
Authors: Michele R Wilson; Jeetvan G Patel; Amber Coleman; Cheryl L McDade; Richard H Stanford; Stephanie R Earnshaw Journal: Int J Chron Obstruct Pulmon Dis Date: 2017-03-24
Authors: Joanne Sloots; Mirthe Bakker; Job van der Palen; Michiel Eijsvogel; Paul van der Valk; Gerard Linssen; Clara van Ommeren; Martijn Grinovero; Monique Tabak; Tanja Effing; Anke Lenferink Journal: Int J Chron Obstruct Pulmon Dis Date: 2021-07-15
Authors: Kirsten Koehorst-Ter Huurne; Marjolein Brusse-Keizer; Paul van der Valk; Kris Movig; Job van der Palen; Christina Bode Journal: Patient Prefer Adherence Date: 2018-09-12 Impact factor: 2.711